Research programme: natural killer cell based therapies - Sorrento/Karolinska Institutet

Drug Profile

Research programme: natural killer cell based therapies - Sorrento/Karolinska Institutet

Alternative Names: NK based therapies - Sorrento/ Karolinska Institutet

Latest Information Update: 19 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Karolinska Institute
  • Developer Karolinska Institute; Sorrento Therapeutics
  • Class Cell therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 11 Jan 2016 Sorrento Therapeutics and Karolinska Institutet agree to co-develop natural killer based cell therapies in Cancer
  • 11 Jan 2016 Early research in Cancer in Sweden (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top